Skip to main content
Top
Published in: European Archives of Psychiatry and Clinical Neuroscience 7/2019

01-10-2019 | Antidepressant Drugs | Original Paper

Pharmacokinetic correlates of venlafaxine: associated adverse reactions

Authors: Georgios Schoretsanitis, Ekkehard Haen, Christoph Hiemke, Katharina Endres, Florian Ridders, Tanja Veselinovic, Gerhard Gründer, Michael Paulzen

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 7/2019

Login to get access

Abstract

To address the potential correlation between plasma concentrations of venlafaxine (VEN), its active metabolite O-desmethylvenlafaxine (ODVEN) and the active moiety, AM, (ODVEN + VEN) and adverse drug reactions (ADR) in a large naturalistic sample of in- and outpatients. We compared plasma concentrations of VEN, ODVEN and AM and dose-adjusted (C/D) levels as well the ODVEN/VEN ratios between patients complaining ADRs, following the Udvalg for Kliniske Undersogelser side effect rating scales (UKU) (n = 114) and patients without ADRs (control group, n = 688) out of a naturalistic database. We also investigated potential pharmacokinetic correlates of the four UKU categories by comparing patients complaining ADRs with those who did not. Based on previous literature we applied different ODVEN/VEN ratio values as cut-offs to split our sample into two groups at a time and compare frequencies of ADRs between the groups. No differences for demographic and pharmacokinetic variables including plasma and C/D concentrations as well as ODVEN/VEN ratios were observed between study groups. Neither the comparisons between females and males nor between elderly and non-elderly patients revealed significant differences (p > 0.05 in all cases). No differences were also reported exploring the patients complaining ADRs from the 4 UKU categories separately. After applying various ODVEN/VEN cut-offs, groups did not display differences in frequencies of ADRs (p > 0.05 in all cases). Our findings do not demonstrate a direct link between venlafaxine metabolism measures and ADRs. Therefore, additional dimensions are needed to be considered in future trials aiming to disentangle the involved aspects of ADRs in patients receiving venlafaxine.
Literature
1.
go back to reference Fogelman SM, Schmider J, Venkatakrishnan K, von Moltke LL, Harmatz JS, Shader RI, Greenblatt DJ (1999) O- and n-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cdna-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 20:480–490CrossRefPubMed Fogelman SM, Schmider J, Venkatakrishnan K, von Moltke LL, Harmatz JS, Shader RI, Greenblatt DJ (1999) O- and n-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cdna-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 20:480–490CrossRefPubMed
2.
go back to reference Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST (1992) Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active o-desmethyl metabolite. J Clin Pharmacol 32:716–724CrossRefPubMed Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST (1992) Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active o-desmethyl metabolite. J Clin Pharmacol 32:716–724CrossRefPubMed
3.
go back to reference Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mossner R, Muller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51:9–62CrossRefPubMed Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mossner R, Muller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51:9–62CrossRefPubMed
4.
go back to reference Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F (2015) Serotonin syndrome: analysis of cases registered in the french pharmacovigilance database. J Clin Psychopharmacol 35:382–388PubMed Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F (2015) Serotonin syndrome: analysis of cases registered in the french pharmacovigilance database. J Clin Psychopharmacol 35:382–388PubMed
5.
go back to reference Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391(10128):1357–1366CrossRefPubMedPubMedCentral Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391(10128):1357–1366CrossRefPubMedPubMedCentral
6.
go back to reference Horst WD, Preskorn SH (1998) Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 51:237–254CrossRefPubMed Horst WD, Preskorn SH (1998) Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 51:237–254CrossRefPubMed
7.
go back to reference Launiainen T, Rasanen I, Vuori E, Ojanpera I (2011) Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Int J Leg Med 125:349–358CrossRef Launiainen T, Rasanen I, Vuori E, Ojanpera I (2011) Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Int J Leg Med 125:349–358CrossRef
8.
go back to reference Sicras-Mainar A, Guijarro P, Armada B, Blanca-Tamayo M, Navarro-Artieda R (2014) Influence of the cyp2d6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences. PLoS One 9:e90453CrossRefPubMedPubMedCentral Sicras-Mainar A, Guijarro P, Armada B, Blanca-Tamayo M, Navarro-Artieda R (2014) Influence of the cyp2d6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences. PLoS One 9:e90453CrossRefPubMedPubMedCentral
9.
go back to reference Batista M, Dugernier T, Simon M, Haufroid V, Capron A, Fonseca S, Bonbled F, Hantson P (2013) The spectrum of acute heart failure after venlafaxine overdose. Clin Toxicol 51:92–95CrossRef Batista M, Dugernier T, Simon M, Haufroid V, Capron A, Fonseca S, Bonbled F, Hantson P (2013) The spectrum of acute heart failure after venlafaxine overdose. Clin Toxicol 51:92–95CrossRef
10.
go back to reference Castanares-Zapatero D, Gillard N, Capron A, Haufroid V, Hantson P (2016) Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism. Forensic Sci Int 266:e48–e51CrossRefPubMed Castanares-Zapatero D, Gillard N, Capron A, Haufroid V, Hantson P (2016) Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism. Forensic Sci Int 266:e48–e51CrossRefPubMed
11.
go back to reference Geber C, Ostad Haji E, Schlicht K, Hiemke C, Tadic A (2013) Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder. Ther Drug Monit 35:279–282CrossRefPubMed Geber C, Ostad Haji E, Schlicht K, Hiemke C, Tadic A (2013) Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder. Ther Drug Monit 35:279–282CrossRefPubMed
12.
go back to reference Jornil J, Nielsen TS, Rosendal I, Ahlner J, Zackrisson AL, Boel LW, Brock B (2013) A poor metabolizer of both cyp2c19 and cyp2d6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. Forensic Sci Int 226:e26–e31CrossRefPubMed Jornil J, Nielsen TS, Rosendal I, Ahlner J, Zackrisson AL, Boel LW, Brock B (2013) A poor metabolizer of both cyp2c19 and cyp2d6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. Forensic Sci Int 226:e26–e31CrossRefPubMed
13.
go back to reference Megarbane B, Bloch V, Deye N, Baud FJ (2007) Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose. Intensive Care Med 33:195–196CrossRefPubMed Megarbane B, Bloch V, Deye N, Baud FJ (2007) Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose. Intensive Care Med 33:195–196CrossRefPubMed
14.
go back to reference Jiang F, Kim HD, Na HS, Lee SY, Seo DW, Choi JY, Ha JH, Shin HJ, Kim YH, Chung MW (2015) The influences of cyp2d6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. Psychopharmacology 232:1899–1909CrossRefPubMed Jiang F, Kim HD, Na HS, Lee SY, Seo DW, Choi JY, Ha JH, Shin HJ, Kim YH, Chung MW (2015) The influences of cyp2d6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. Psychopharmacology 232:1899–1909CrossRefPubMed
15.
go back to reference Unterecker S, Pfuhlmann B, Kopf J, Kittel-Schneider S, Reif A, Deckert J (2015) Increase of heart rate and QTC by amitriptyline, but not by venlafaxine, is correlated to serum concentration. J Clin Psychopharmacol 35:460–463PubMed Unterecker S, Pfuhlmann B, Kopf J, Kittel-Schneider S, Reif A, Deckert J (2015) Increase of heart rate and QTC by amitriptyline, but not by venlafaxine, is correlated to serum concentration. J Clin Psychopharmacol 35:460–463PubMed
16.
go back to reference Hefner G, Hahn M, Hohner M, Roll SC, Klimke A, Hiemke C (2019) QTC time correlates with amitriptyline and venlafaxine serum levels in elderly psychiatric inpatients. Pharmacopsychiatry 52:38–43CrossRefPubMed Hefner G, Hahn M, Hohner M, Roll SC, Klimke A, Hiemke C (2019) QTC time correlates with amitriptyline and venlafaxine serum levels in elderly psychiatric inpatients. Pharmacopsychiatry 52:38–43CrossRefPubMed
17.
go back to reference Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, Lackner K, Hartter S (2006) Cyp2d6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 31:493–502CrossRefPubMed Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, Lackner K, Hartter S (2006) Cyp2d6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 31:493–502CrossRefPubMed
18.
go back to reference Ozbey G, Celikel FC, Cumurcu BE, Kan D, Yucel B, Hasbek E, Percin F, Guzey IC, Uluoglu C (2017) Influence of abcb1 polymorphisms and serum concentrations on venlafaxine response in patients with major depressive disorder. Nord J Psychiatry 71:230–237CrossRefPubMed Ozbey G, Celikel FC, Cumurcu BE, Kan D, Yucel B, Hasbek E, Percin F, Guzey IC, Uluoglu C (2017) Influence of abcb1 polymorphisms and serum concentrations on venlafaxine response in patients with major depressive disorder. Nord J Psychiatry 71:230–237CrossRefPubMed
19.
go back to reference Neuner T, Hubner-Liebermann B, Haen E, Hausner H, Felber W, Wittmann M, Agate (2011) Completed suicides in 47 psychiatric hospitals in Germany—results from the agate-study. Pharmacopsychiatry 44:324–330CrossRefPubMed Neuner T, Hubner-Liebermann B, Haen E, Hausner H, Felber W, Wittmann M, Agate (2011) Completed suicides in 47 psychiatric hospitals in Germany—results from the agate-study. Pharmacopsychiatry 44:324–330CrossRefPubMed
20.
go back to reference Fischer-Barnicol D, Lanquillon S, Haen E, Zofel P, Koch HJ, Dose M, Klein HE, Working Group ‘Drugs in P (2008) Typical and atypical antipsychotics—the misleading dichotomy. Results from the working group ‘drugs in psychiatry’ (agate). Neuropsychobiology 57:80–87CrossRefPubMed Fischer-Barnicol D, Lanquillon S, Haen E, Zofel P, Koch HJ, Dose M, Klein HE, Working Group ‘Drugs in P (2008) Typical and atypical antipsychotics—the misleading dichotomy. Results from the working group ‘drugs in psychiatry’ (agate). Neuropsychobiology 57:80–87CrossRefPubMed
22.
go back to reference Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The uku side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1–100CrossRefPubMed Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The uku side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1–100CrossRefPubMed
23.
go back to reference Paul L, Musshoff F, Aebi B, Auwärter V, Krämer T, Peters F, Skopp G, Aderjan R, Herbold M, Schmitt G (2009) Richtlinie der gtfch zur qualitätssicherung bei forensisch-toxikologischen untersuchungen. Toxichem Krimtech 76:142–176 Paul L, Musshoff F, Aebi B, Auwärter V, Krämer T, Peters F, Skopp G, Aderjan R, Herbold M, Schmitt G (2009) Richtlinie der gtfch zur qualitätssicherung bei forensisch-toxikologischen untersuchungen. Toxichem Krimtech 76:142–176
25.
go back to reference Preskorn SH, Kane CP, Lobello K, Nichols AI, Fayyad R, Buckley G, Focht K, Guico-Pabia CJ (2013) Cytochrome p450 2d6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry 74:614–621CrossRefPubMed Preskorn SH, Kane CP, Lobello K, Nichols AI, Fayyad R, Buckley G, Focht K, Guico-Pabia CJ (2013) Cytochrome p450 2d6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry 74:614–621CrossRefPubMed
26.
go back to reference Schoretsanitis G, Haen E, Hiemke C, Fay B, Unholzer S, Correll CU, Grunder G, Paulzen M (2018) Sex and body weight are major determinants of venlafaxine pharmacokinetics. Int Clin Psychopharmacol 33(6):322–329CrossRefPubMed Schoretsanitis G, Haen E, Hiemke C, Fay B, Unholzer S, Correll CU, Grunder G, Paulzen M (2018) Sex and body weight are major determinants of venlafaxine pharmacokinetics. Int Clin Psychopharmacol 33(6):322–329CrossRefPubMed
27.
go back to reference Reis M, Lundmark J, Bjork H, Bengtsson F (2002) Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit 24:545–553CrossRefPubMed Reis M, Lundmark J, Bjork H, Bengtsson F (2002) Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit 24:545–553CrossRefPubMed
28.
go back to reference Garcia S, Schuh M, Cheema A, Atwal H, Atwal PS (2017) Palpitations and asthenia associated with venlafaxine in a cyp2d6 poor metabolizer and cyp2c19 intermediate metabolizer. Case Rep Genet 2017:6236714PubMedPubMedCentral Garcia S, Schuh M, Cheema A, Atwal H, Atwal PS (2017) Palpitations and asthenia associated with venlafaxine in a cyp2d6 poor metabolizer and cyp2c19 intermediate metabolizer. Case Rep Genet 2017:6236714PubMedPubMedCentral
29.
go back to reference Wijnen PA, Limantoro I, Drent M, Bekers O, Kuijpers PM, Koek GH (2009) Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking cyp2d6 activity. Ann Clin Biochem 46:527–530CrossRefPubMed Wijnen PA, Limantoro I, Drent M, Bekers O, Kuijpers PM, Koek GH (2009) Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking cyp2d6 activity. Ann Clin Biochem 46:527–530CrossRefPubMed
30.
go back to reference Reis M, Aamo T, Spigset O, Ahlner J (2009) Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit 31:42–56CrossRefPubMed Reis M, Aamo T, Spigset O, Ahlner J (2009) Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit 31:42–56CrossRefPubMed
31.
go back to reference Karlsson L, Hiemke C, Carlsson B, Josefsson M, Ahlner J, Bengtsson F, Schmitt U, Kugelberg FC (2011) Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the p-glycoprotein knockout mice model. Psychopharmacology 215:367–377CrossRefPubMed Karlsson L, Hiemke C, Carlsson B, Josefsson M, Ahlner J, Bengtsson F, Schmitt U, Kugelberg FC (2011) Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the p-glycoprotein knockout mice model. Psychopharmacology 215:367–377CrossRefPubMed
32.
go back to reference Karlsson L, Zackrisson AL, Josefsson M, Carlsson B, Green H, Kugelberg FC (2015) Influence of cyp2d6 and cyp2c19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases. Pharmacogenom J 15:165–171CrossRef Karlsson L, Zackrisson AL, Josefsson M, Carlsson B, Green H, Kugelberg FC (2015) Influence of cyp2d6 and cyp2c19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases. Pharmacogenom J 15:165–171CrossRef
33.
go back to reference Chua EW, Foulds J, Miller AL, Kennedy MA (2013) Novel cyp2d6 and cyp2c19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetine. Pharmacogenet Genom 23:494–497CrossRef Chua EW, Foulds J, Miller AL, Kennedy MA (2013) Novel cyp2d6 and cyp2c19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetine. Pharmacogenet Genom 23:494–497CrossRef
Metadata
Title
Pharmacokinetic correlates of venlafaxine: associated adverse reactions
Authors
Georgios Schoretsanitis
Ekkehard Haen
Christoph Hiemke
Katharina Endres
Florian Ridders
Tanja Veselinovic
Gerhard Gründer
Michael Paulzen
Publication date
01-10-2019
Publisher
Springer Berlin Heidelberg
Published in
European Archives of Psychiatry and Clinical Neuroscience / Issue 7/2019
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-019-01005-0

Other articles of this Issue 7/2019

European Archives of Psychiatry and Clinical Neuroscience 7/2019 Go to the issue